Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.55% | 1.39% | -25.06% | 2.36% | -39.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.06% | 10.14% | -1.99% | 34.86% | 34.28% |
| Operating Income | -5.06% | -10.14% | 1.99% | -34.86% | -34.28% |
| Income Before Tax | -468.11% | 15.59% | -16.13% | -34.01% | 108.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -468.11% | 15.59% | -16.13% | -34.01% | 108.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -468.11% | 15.59% | -16.13% | -34.01% | 108.02% |
| EBIT | -5.06% | -10.14% | 1.99% | -34.86% | -34.28% |
| EBITDA | -5.15% | -10.49% | 1.94% | -34.56% | -34.17% |
| EPS Basic | -444.34% | 21.05% | -7.05% | -19.67% | 107.16% |
| Normalized Basic EPS | -445.45% | 20.88% | -7.26% | -19.47% | 107.13% |
| EPS Diluted | -444.34% | 21.05% | -7.05% | -19.67% | 107.16% |
| Normalized Diluted EPS | -445.45% | 20.88% | -7.26% | -19.47% | 107.13% |
| Average Basic Shares Outstanding | 6.69% | 6.93% | 8.55% | 12.09% | 12.28% |
| Average Diluted Shares Outstanding | 6.69% | 6.93% | 8.55% | 12.09% | 12.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |